FindTrial
Sign In

A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderate atopic dermatitis

A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderate atopic dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002594-23-DE
Enrollment
Unknown
Registered
2005-01-25
Start date
2005-03-10
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Trade Name: Ekzevowen derma Product Name: Ekzevowen derma Pharmaceutical Form: Ointment Other descriptive name: mother tincture of Centella asiatica Concentration unit: % (W/W) percent weight/weight C

Sponsors

Weber & Weber GmbH & Co.KG
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Caucasian males and females betwen 18 and 65 years of age with mild to moderate atopic dermatitis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Use of glucocorticoids 4 weeks prior to study entry Systemic use of antihistamines, antipruritics or immunosuppressants 2 weeks prior to study entry Any treatment of target area for at least 2 weeks prior to study entry

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the efficacy and safety of an herbal ointment in mild to moderate atopic dermatitis in adults;Secondary Objective: ;Primary end point(s): Local SCORAD: summary score for erythema, edema/papulation, oozing/crust, excoriation and lichenification (4 point scale)—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026